Skip to main content
Fig. 4 | BMC Medicine

Fig. 4

From: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer

Fig. 4

Efficacy of osimertinib combined with anlotinib for osimertinib-resistant xenografts in vitro. A The weight curve of humanized mice in each group during treatment. B The tumor volume curve of humanized mice during treatment. C Measurement of fresh xenograft tumor tissues after the mice were euthanized at the end of treatment (*, P<0.05; **, P<0.01)

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us